Table 2.
Assumptions for budget impact analysis
| 1. The annual economic model is good for 15 years | ||
| 2. Annual budgets per person (costs in the economic model [12]) | ||
| Screening | ||
| Dipstick test only | ¥ 267 (¥267) | |
| Serum Cr assay only | ¥138 (¥138) | |
| Dipstick test and serum Cr assay | ¥342 (¥342) | |
| Detailed examination at clinic or hospital | ¥17,500 (¥25,000) | |
| CKD treatment | ||
| Stage 1 | ¥84,000 (¥120,000) | |
| Stage 2 | ¥102,900 (¥147,000) | |
| Stage 3 | ¥235,900 (¥337,000) | |
| Stage 4 | ¥555,100 (¥793,000) | |
| Stage 5 | ¥691,600 (¥988,000) | |
| ESRD treatment | ¥5,880,000 (¥6,000,000) | |
| Heart attack treatment | ||
| 1st year | ¥1,946,000 (¥2,780,000) | |
| 2nd year and after | ¥125,300 (¥179,000) | |
| Stroke treatment | ||
| 1st year | ¥700,000 (¥1,000,000) | |
| 2nd year and after | ¥125,300 (¥179,000) | |
| 3. A population projection for Japan [17] is used and sex and age structure is applied for the annual economic model | ||
| 4. The uptake of SHC is fixed at 41.3 % for 15 years [18] | ||